Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals announced that the EMA's CHMP has issued a positive opinion recommending expanded European marketing authorization for IMCIVREE (setmelanotide) to treat obesity and hunger control in patients with acquired hypothalamic obesity due to hypothalamic injury or impairment. This follows the recent FDA approval in the U.S., highligh…